



Poster Session 4
5:30 – 7:00 p.m.
Thursday, December 13

P4-01-01: An Innovative Approach to Alleviating Fatigue in Metastatic Breast Cancer Patients	Eliza Brufsky
P4-01-02: QUALITY OF LIFE IN BREAST CANCER PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY IN A BRAZILIAN CANCER CENTER: THE IMPACT ON YOUNG WOMEN	FABIANA MAKDISSI
P4-01-03: Beyond Aesthetics: Cold Cap Hair Preservation Correlates with Lower Chemotherapy Symptom Burden in Patients with Breast Cancer	Talar Televizian
P4-01-04: Adaptation of the EORTC Quality of Life Breast Cancer Module for male Breast Cancer – Results of the Phase I-II module	Vesna Bjelic-Radisic
P4-01-05: Impact of treatment for early-stage breast cancer on patient quality of life: a large single-institution experience in Brazil	Adriana Kahn
P4-01-06: Evaluation of the results of fully implantable catheters for chemotherapy (cervical and brachial region) in cancer patients	Marina Toledo
P4-01-07: The contribution of Acceptedance, awareness of illness, social contexts and economic status to mental health among women with breast cancer	Raffaela Daria Giovanna Sartori
P4-01-08: PYNK at 20: From SABCS Inspiration to Multisite Clinical, Research, and Educational Program for Young Women with Breast Cancer	Sandy Vuong
P4-01-09: REAL-LIFE OUTCOMES OF A 10-YEAR ONCOFERTILITY PROGRAM IN EARLY BREAST CANCER PATIENTS	Bernardo Pereira
P4-01-10: Sexual well-being and its association with breast surgery indications: an exploratory study	Sileny Han
P4-01-11: Patient-reported outcomes assessment using mobile applications in the HR+/Her2- breast cancer adjuvant setting.	Federico Waisberg

P4-01-12: Advanced Breast Cancer, Comorbidities, and Overall Survival: An Integrated Review	Abbey Kaler
P4-01-13: Are we tired of talking about sleep? Insomnia amongst breast cancer patients	Emily Scott
P4-01-14: The impact of early breast cancer on psychological resilience, distress levels and perception of health, a longitudinal study	Anuska Budisavljevic
P4-01-15: Treatment tolerability and adherence in people living with metastatic and non-metastatic breast cancer: Findings from the Cancer Experience Registry	Erica Fortune
P4-01-16: Comprehensive Genomic Characterization of ILC Organoids: A BCRF Legacy Project Initiative	Jagmohan Hooda
P4-01-17: Uncovering of NRAGE/JNK and PI3K/AKT pathways through serial WGS of breast cancer patients	byeongju kang
P4-01-18: NEDD9 expression as an indicator for pathological complete response (pCR) in early-stage HER2-positive breast cancer patients undergoing neoadjuvant therapy	Bei Jiang
P4-01-19: Clinical impact of MRD detection via ctDNA tumor-agnostic assay in early-stage breast cancer patients: a real-world experience	Caterina Gianni
P4-01-20: Impact of neoadjuvant chemotherapy on PD-L1 status in patients with high-risk early-stage triple-negative breast cancer	Ariadna Roqué-Lloveras
P4-01-21: The clinical significance of disialoganglioside GD2 synthases in breast cancer	Niamh O'Neill
P4-01-22: Serum Thymidine Kinase as a Biomarker for Response Beyond Progression in First-line CDK 4/6 Inhibitors: Insights from the Randomized Phase II MAINTAIN Trial	Ruth Sacks
P4-01-23: Potential prognostic Value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer	Fangchao Zheng
P4-01-24: Common determinants of CDK4/6 inhibitor-based therapy in metastatic HR+/HER2- breast cancer	Erik Knudsen
P4-01-25: THE ROLE OF SERUM THYMIDINE KINASE 1 ACTIVITY (TK1) AS A PROGNOSTIC FACTOR Y LUMINAL HER2 NEGATIVE BREAST CANCER	SERAFIN MORALES
P4-01-26: The Xpert® Breast Cancer Insight test predicts distant recurrence and overall survival in estrogen receptor-positive, HER2-negative early breast cancer: A validation study in ABCSG Trial 8	Martin Filipits

P4-01-27: Detection, isolation, and genetic characterization of circulating tumor cells from the cerebrospinal fluid of breast cancer patients with leptomeningeal metastasis	André Franken
P4-01-28: The role of ctDNA clearance in the adjuvant setting in triple negative breast cancer patients with residual tumors after neoadjuvant chemotherapy in the TRICIA trial.	Mark Basik
P4-01-29: Identification of Urinary microRNA as Potential Biomarkers in Breast Cancer Patients	Yuka Inoue
P4-01-30: Proteogenomic profiles of HER2-positive breast cancer and response to neoadjuvant anti-HER2 treatment	Kang Wang
P4-02-01: Clinical and biological markers to improve the identification of frailty in patients with early breast cancer	Emanuela Risi
P4-02-02: Hospitalizations and emergency visits for Ontario breast cancer patients undergoing neoadjuvant chemotherapy with pembrolizumab: A population-based analysis	Gary Ko
P4-02-03: Transparency for patient assistance and compassionate use programs for high-cost intravenous and oral therapies in breast cancer patients at an NCI-designated cancer center	Jina Yun
P4-02-04: Development of ASSESS, a breast cancer decision support tool using SEER data and treatment benefit estimates from randomized adjuvant therapy trials.	Lajos Pusztai
P4-02-05: Real-world treatment patterns of neoadjuvant chemotherapy delays in operable breast cancer	Margaux Wooster
P4-02-06: Assessing the True Cost of Breast Cancer Screening: Chargemaster, Payer, and Cash Price Discrepancies for Mammography	Mason Alford-Holloway
P4-02-07: Uptake of Ovarian Function Suppression Over Time and Endocrine Therapy Adherence Among Premenopausal Women with Breast Cancer	Dawn Hershman
P4-02-08: Comparative budget impact of CDK 4/6 inhibitors at a Mexican public healthcare institution	Karla Centelles-López
P4-02-09: Community Socio-geographic Distress Predicts Metastatic Breast Cancer at Diagnosis and Delays in Treatment Initiation	Priyanka Parmar
P4-02-10: Validating Navya Earthshot: An AI Driven Point of Care Solution for Guideline Adherent Treatment Planning in a Decentralized Cancer Care Model.	Umesh Mahantshetty

P4-02-11: Outcomes of Susan G. Komen’s “Navigating People with Metastatic Breast Cancer” Patient Navigation Training Course	Julie McMahon
P4-02-12: Incidence and Survival Trends in Young Women (Aged 20-49) with Breast Cancer: SEER analysis.	Nikhila Aimalla
P4-02-13: The global failure of mammography screening accessibility – a systematic literature review	Carlos Barrios
P4-02-14: A Multi-Practice Quality Initiative Focused on HER2+ and HER2low Metastatic Breast Cancer	Mike Gart
P4-02-15: Potential Drug-Drug Interactions and Related Safety Considerations in Patients with Metastatic Breast Cancer Treated with Ribociclib	Claire Sathe
P4-02-16: Genetic Spectrum and Prevalence of Hereditary Breast and Ovarian Cancer Genes in Ceará's Families, Brazil: A Retrospective Study on Germline Mutations and Regional Variants	DANIELLE MAIA
P4-02-17: Toward Universal Germline Genetic Testing for Patients with Breast Cancer, Perspectives from a Recourse-Restricted Country	Sarah Abdel-Razeq
P4-02-18: Change in MRI Background Contrast Enhancement (BPE), Fibroglandular Volume, and Hormones with Bazedoxifene and Conjugated Estrogens	Carol Fabian
P4-02-19: Development and Validation of a Genetic Risk Prediction Model for Breast Cancer: The Prognostic Role of SNAI1 and CDH1 in Treatment Response and Patient Survival	Chieh-Ni Kao
P4-02-20: Investigating Age-Dependent Breast Cancer Dynamics in a Mouse Model	Yun Zhang
P4-02-21: Disparities among patients evaluated in dedicated high-risk breast cancer clinic	Helen Yuan
P4-02-22: Temporal Changes in Breast Cancer Reproductive Risk Factors Among Women in Southwest Nigeria: Data from The Nigerian Breast Cancer Survey	Gideon Dosunmu
P4-02-23: RISK-REDUCING MASTECTOMIES FOR BREAST CANCER IN BRAZILIAN PATIENTS UNDERGOING GERMINATIVE MULTIGENE PANEL TO BREAST CANCER: impact of results on the decision of conduct	Bárbara Duarte
P4-02-24: Frequency of HER2-low status among patients with breast cancer and germline BRCA1/2 pathogenic variants	Ana Maria Ulbricht Gomes
P4-02-25: Dietary-Restriction Genes as Modulators of Breast Cancer Risk Through Metabolic Pathways	Yiyin Zhang

P4-02-26: CHEK2-Associated Cancer Risk Beyond 1100delC: Insights from a Northeast Brazilian Cohort	DANIELLE MAIA
P4-02-27: Do High-Risk Breast Cancer Patients Belonging to Ethnic Minority Groups Undergo Adequate Genetic Testing for Early Detection and Treatment	Zachary C Bitan
P4-02-28: Decisional challenges regarding risk-reducing surgery for BRCA1/2 and PALB2 women	Catarina Relvas
P4-02-29: Epigenetic aging as a tumor marker for predicting breast cancer susceptibility	Su Yon Jung
P4-02-30: Germline Mismatch Repair Gene Mutation (MLH1) in Breast and Endometrial Cancer: A Case Report	Marygrace Margie Mesina
P4-03-01: Alarming levels of obesity and overweight in Brazilian women with early-stage ER+ breast cancer in adjuvant endocrine therapy	Daniele Assad-Suzuki
P4-03-02: Open	
P4-03-03: Outcomes and Survivorship in Geriatric Breast Cancer Patients with Chemotherapy Dose Reduction.	Huy Nong
P4-03-04: Effect of a Weight Loss/Exercise Program and Hormone Therapy on Peripheral Inflammatory Markers in ER+ Breast Cancer Survivors	Martha Kato
P4-03-05: Effect of Phesgo® on Time Toxicity in Breast Cancer Patients	Minori Antoh
P4-03-06: A Single-Center Review of the Impact of an Integrated Women's Health Clinic for Breast Cancer Patients Who Received Cancer-Directed Treatment	Deanna Huffman
P4-03-07: Implementing Quality of Life assessment in breast cancer patients in India	Madhuri Taranikanti
P4-03-08: Pre- and post-diagnostic healthy lifestyle and cardiovascular disease among breast cancer survivors	Qiang Liu
P4-03-09: Breast Cancer Long Survivorship Program Experience in Mexico City	Laura Kay Lagarde-Santillan
P4-03-10: Body image and sexuality concerns among young women with breast cancer in a Mexican Population	Saul Campos-Gomez
P4-03-11: Patient and health care provider perspectives on oral versus intramuscular endocrine therapy for locally advanced or metastatic breast cancer	Rebecca Speck
P4-03-12: How do Arab World Breast Cancer Survivors feel about De-escalation of Treatment?	Rita Sakr

P4-03-13: Machine learning-based sentiment analysis related to Trastuzumab Deruxtecan in online forums	Nawale Hajjaji
P4-03-14: A review of the evidence for survival benefit of six lifestyle medicine interventions in breast cancer patients	Laura Wright
P4-03-15: Clinical characterization of taxanes chemotherapeutic regimens-induced peripheral neurotoxicity and establishment of a risk model	Bin Yang
P4-03-16: Comparison of analytical and prognostic performance among various Artificial Intelligence models for Tumor Infiltrating Lymphocytes scoring in Triple Negative Breast Cancer: An independent validation on a prospective cohort	Nikolaos Tsiknakis
P4-03-17: Enhanced spatial detection of post-neoadjuvant breast cancer minimal residual disease by tissue-based Cancer Personalized Profiling by Deep Sequencing.	Julia Ransohoff
P4-03-18: Chimerizing the HER2 receptor for functional and immunologic studies with α HER2 antibody-drug conjugates	Julia Steele
P4-03-19: Plasma-based prediction of prognosis, receptor status and organ involvement among patients receiving antibody-drug conjugates for metastatic breast cancer	Paolo Tarantino
P4-03-20: Molecular characterization of estrogen receptor (ER)+/HER2- breast cancer unveils a biologically and clinically distinct entity with ERBB2 hemizygous deletion (ERBB2del)	Paolo Tarantino
P4-03-21: Limiting Over- and Under-Treatment of DCIS: Ten Year Breast Recurrence Rates with Personalized Management Utilizing the 7-Gene Biosignature as Compared to Clinicopathologic Factors Alone	Frank Vicini, Karuna Mittal
P4-03-22: Inhibiting JNK signaling enhances the antitumor efficacy of macrophage-targeting agents in triple-negative breast cancer by inducing an immunoactive tumor microenvironment	Xuemei Xie
P4-03-23: Preclinical investigation for the mechanisms of action of PARP inhibition in combination with trastuzumab deruxtecan (T-DXd) in triple negative breast cancer (TNBC)	Adrian Gonzalez Gonzalez
P4-03-24: Septin 9 isoform expression and response to taxane treatment in breast cancer patients	Jacob Essif
P4-03-25: Actionable gene alterations affecting the PI3K/AKT and MAPK signaling pathways in breast cancer	Gargi Basu
P4-03-26: MINDY1 role and exceptional response to CDK inhibitors in metastatic breast cancer	Elena Fountzilias
P4-03-28: Validation of an AI-based solution for breast cancer risk stratification using routine digital histopathology images	Abhinav Sharma

P4-03-29: Patient reported anxiety levels during ctDNA surveillance in early stage triple negative and hormone positive breast cancer	Devora Isseroff
P4-03-30: GPR56/ADGRG1 promotes the progression of triple-negative breast cancer by enhancing PKM2/LDH-mediated glycolysis via the PI3K/AKT/mTOR/HIF-1 α pathway	Haizhu Chen
P4-04-01: Disparities in the dissemination of new breast cancer treatments in the United States	Jennifer Caswell-Jin
P4-04-02: Implementing Decision Aid Use and Shared-Decision Making in Breast Cancer Screening: A Scoping Review	Rama Alkhalidi
P4-04-03: Establishment of an Inflammatory Breast Cancer Program: A Quality Improvement and Research Effort	Heather LeFebvre
P4-04-04: Leveraging Technology to Improve Access to Clinical Trials in Underrepresented Populations within a Safety-Net Institution	Kalyani Narra
P4-04-05: Enhancing Clinicians' Knowledge and Competence Regarding the Use of Antibody Drug Conjugates (ADCs) in HER2+ Advanced Breast Cancer: Impact of Continuing Medical Education	Tamima Ashraf
P4-04-06: Connecting Care: Telemedicine Breaks Barriers for Low-Income Brazilians Battling Breast Cancer	Gabriel D'Alessandro
P4-04-07: Harnessing Cognitive Engineering to Understand Breast Cancer Patient Decision Making	Megan Salwei
P4-04-08: Delays from Self-Detection to Treatment of Breast Cancer in the South Fluminense Region: A Cross-Sectional Analysis	Heloisa Resende
P4-04-09: Supporting the Knowledge Translation of Exercise Recommendations for People with Bone Metastases using Experience-based Co-Design	Diego Malon Gimenez
P4-04-10: Improving early breast cancer care coordination - Digital care pathway: Implementation and Pivotal Results	Sónia Oliveira
P4-04-11: Managing Wait Time Between Surgery and Treatment Initiation Plan in Patients with Breast Cancer: a Mixed-method Approach	Wissam Saliba
P4-04-12: Covid 19 pandemic: effects on the diagnosis and treatment of breast cancer in two large teaching hospitals in the city of São Paulo - Brazil	MARCIA SILVA
P4-04-13: Single-center Relative and Cause-Specific Survival in Breast Cancer	Patrick Neven
P4-04-14: Economic analysis of germline genetic testing to assess for hereditary breast cancer: a systematic review	Gebra Cuyún Carter

P4-04-15: Oncofertility and Breast Cancer: An Analysis of Perception and Practices Among Specialists	Erika Bushatsky
P4-04-16: Radiation safety, feasibility and improved results quality of prone versus supine MDCT position "Modus Spiridonov" for breast cancer staging	Yordan Spiridonov
P4-04-17: TFX06 shows remarkable safety and extracranial and intracranial efficacy in patients with ER+ /HER2- breast cancer in a phase 1 study	Charles Ding
P4-04-18: AI based Thermaltyx for management of Breast Pain in Primary Care	Geetha Manjunath
P4-04-19: Characterizing Nanomechanical Properties of Skin and Soft Tissue in Postmastectomy Implant Reconstruction	Papa Diogop Ndiaye
P4-04-20: Contrast-enhanced mammography-guided biopsy enhances early detection of breast cancer through precise target selection in extensive suspicious microcalcification diagnosed in screening mammography	Wai-Shan Chung
P4-04-21: Frozen gloves can prevent chemotherapy-induced nail pigmentation of the hand in early-stage breast cancer patients: a prospective self-matched case-control study	Fei Xu
P4-04-22: Impact of screening mammography on breast cancer outcomes in women aged 80 and over	Siu-Yuan Huang
P4-04-23: Reverse-sequence Endoscopic Versus Conventional Open Nipple-Sparing Mastectomy with Implant-based Breast Reconstruction: A Single-center Prospective Cohort Study (RECO study)	Tianyuan Li
P4-04-24: Cytokeratin 19 mRNA copy number by one-step nucleic acid amplification (OSNA) in the sentinel lymph node biopsy (SLNB) as prognostic factor in Luminal early Breast Cancer (LeBC).	Maria Yeray Rodríguez Garcés
P4-04-25: HER2 Assay for the Detection of Low Expressing HER2 (IHC Score 1+/0) in Circulating Tumor Cells Enriched from Peripheral Blood using the CELLSEARCH [®] System	Damodara Gullipalli
P4-04-26: A New Option for post-CDK4/6is Resistance Era: Multicenter Real-world Study of Anlotinib-based Combination Therapy in Hormone Receptor-positive Metastatic Breast Cancer Resistant to CDK4/6 Inhibitors	Quchang Ouyang
P4-04-27: Next generation antibody drug conjugates targeting HER2 and TROP2: Multi-Payload Conjugates ^{â,,ç} targeting orthogonal mechanisms of cell killing	Marco Lobba

P4-04-28: PF-07248144, a first-in-class KAT6 inhibitor, in patients with HR+ HER2 ⁺ metastatic breast cancer: Updated results from phase 1 dose expansion study	Toru Mukohara
P4-04-29: The Impact of Race and Neighborhood on Young Breast Cancer Patients	Melanie Sheen
P4-04-31: A phase Ib/II study of PARPi Mefuparib Hydrochloride (CVL218) in combination with PD-1 inhibitor plus chemotherapy in metastatic or recurrent triple-negative breast cancer (TNBC)	Jian Zhang
P4-04-32: Clinical study of 99mTc-Rituximab combined with dyes double tracing for axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer	Hui Zhang
P4-04-34: Use of Intravaginal Physical Energy for Treating Genitourinary Syndrome of Menopause in Breast Cancer Survivors: A Systematic Review	Nicoli Serquiz
P4-04-35: Thioredoxin-Interacting Protein (TXNIP) as a Key Regulator of Tumor Growth and Progression	Liang Liu
P4-04-36: Mixed Reality-Assisted Breast-Conserving Surgery Using HoloLens 2: Initial Results from a Phase II Trial	RYOSUKE MOHRI
P4-04-37: SS Induces BRCA1 Reduction and Sensitizes Breast Cancer Cells to PARP Inhibitor Therapy	Jiaqi Chen
P4-04-38: Real world study of racial disparities in toxicities of Antibody Drug Conjugates in advanced breast cancer treatment	Shista Priyadarshini
P4-04-39: Excellent and Prolonged Response to Sacituzumab-govitecan in Triple Negative mBC	Elena Giontella Elena Fiorio
P4-04-40: Sentinel Lymph Node Biopsy in the Prognosis of Women Undergoing Neoadjuvant Chemotherapy for Breast Cancer Treatment including advanced Stages: A Real-World Study in a public hospital in Brazil	Rafael Machado
P4-04-41: The impacts of neoadjuvant or adjuvant chemotherapy on surgical complications and cosmetic outcomes of reverse-sequence endoscopic nipple-sparing-mastectomy with immediate breast reconstruction.	Kawun Chung
P4-04-42: A novel 3D-printed scaffold for patient-specific partial breast reconstruction: A Prospective, Single-Arm Clinical Trial	Juliang Zhang
P4-05-01: Retrospective Analysis of fam-Trastuzumab Deruxtecan Treatment in Advanced Breast Cancer Patients: Real World Experience at Mayo Clinic in Arizona (2022-2024)	Drake Alton

P4-05-02: Strategies for premedication and neutropenia prophylaxis in sacituzumab govitecan treatment of patients with triple-negative breast cancer: multicenter insights	Joanna Streb
P4-05-03: Acceptability and feasibility of early cancer psychiatry consultation in management of aromatase inhibitor-induced musculoskeletal symptoms (AIMSS) in early-stage hormone receptor positive breast cancer	Oday Elmanaseer
P4-05-04: Evaluating the ePRO-based follow-up system (Pink Ribbon Diary) on quality of life and treatment adherence in patients with breast cancer receiving CDK4/6 inhibitors (JPRO-B)	Rie Ozeki
P4-05-05: Investigating the Efficacy and Safety of a Dose-Dense Paclitaxel, Cyclophosphamide with Trastuzumab in Stage I-III Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer	Jairam Krishnamurthy
P4-05-06: The role of music therapy, guided meditation and acupuncture in attenuating chemotherapy-induced cognitive impairment in breast cancer.	Jules Cohen
P4-05-07: Estimating Clonal Hematopoiesis Prevalence in Women with Breast Cancer: A Meta-Analytic Approach Stratified by Age	DANIELLE MAIA
P4-05-08: Impact of antiemetic prophylaxis on maintaining dose intensity of trastuzumab deruxtecan in HER2-positive advanced breast cancer	Junghoon Shin
P4-05-09: ERIBULIN'S ARCANE ODYSSEY: UNRAVELING STEVEN JOHNSON SYNDROME (SJS) /TOXIC EPIDERMAL NECROLYSIS (TEN) IN METASTATIC BREAST CANCER	ARTI GOEL
P4-05-10: Title: Outcomes of Chemotherapy-Induced Peripheral Neuropathy (CIPN): Psychological Impact and Predictive Modeling	Carla Bou Dargham
P4-05-11: Physical changes caused by low-dose Tamoxifen therapy	Rinat Yerushalmi
P4-05-12: A meta-analysis of adverse events associated with anti-PD-1 therapy	Balazs Gyorffy
P4-05-13: The quality of life of women after treatment of breast cancer is lymphostasis as a life-changing complication.	MARHA MUKUEVA
P4-05-14: Prognostic factors of one versus two pregnancy associated breast cancer	Maxim Izquierdo
P4-05-15: EVOLVE: Harnessing the Power of AI, RWD, and Precision Education to Minimize Breast Cancer Care Disruptions	Shashi Shankar
P4-05-16: FATTY ACID PROFILE ON RED BLOOD CELL MEMBRANE PREDICT BREAST CANCER SUBTYPE	Francisco Acevedo

P4-05-17: PER2 Expression as an Independent Predictor of Shorter Disease-Free Survival in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy	Rodrigo Goncalves
P4-05-18: Modelling MHC-I downregulation in triple negative breast cancer to rescue resistance to ICB using diacylglycerol kinase inhibitors	Jacey Marshall
P4-05-19: Magnetic Resonance Elastography: A Novel Imaging tool to predict response in patients undergoing Neo-Adjuvant Chemotherapy for Breast Cancer	Aaditya Sinha
P4-05-20: Development and validation of a combined ultrasound-pathology model to predict axillary status after neoadjuvant systemic therapy in breast cancer	Jue Wang
P4-05-21: Dynamic ctDNA tracking stratifies individual relapse risk for early triple negative breast cancer patients receiving neoadjuvant chemotherapy	Qiang Liu
P4-05-22: Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer	Sandra Hammer
P4-05-23: Quantitative Diffusion Weighted Imaging for Predicting Response to Neoadjuvant Therapy in Patients with Inflammatory Breast Cancer	Huong (Carisa) Le-Petross
P4-05-24: Point mutations (PM), gene amplifications (GA) and variants of unknown significance (VUS) detected by next-generation sequencing (NGS) in a real-world sample of metastatic breast cancer (MBC)	Marcus Lee
P4-05-25: Impact of Estrogen Receptor Targeting Drugs on a Novel Epithelial-Mesenchymal Transition Pathway in Endocrine Resistant Breast Cancer: Implications for Metastasis	Nivida Shete
P4-05-26: MamaTrace - A cell-free DNA methylation plasma only assay for minimal residual disease detection in breast cancer	Bodour Salhia
P4-05-27: Comparative analysis of TROP2 expression in tumor tissues and circulating tumor cells (CTCs) in the peripheral blood of patients with triple negative breast cancer	Dimitrios Mavroudis
P4-05-28: The cytokine profile correlates with less tumor-infiltrating lymphocytes in luminal A breast cancer	Aoi Oshiro
P4-05-29: ctDNA and serum thymidine kinase activity as tools to stratify ER+/HER2- metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibitors: preliminary results of the TIRESIAS trial	Luca Malorni

P4-05-30: MUC4 downregulation by TNF blockade enhances trastuzumab deruxtecan antitumor effect in a HER2-positive breast cancer model	Roxana Schillaci
P4-06-01: Comprehensive Analysis of Breast Cancer Treatment and Patient Characteristics in a Nationwide Cross-Sectional Study	Bela Mrinakova
P4-06-02: Integration of simulated triple assessment clinics into undergraduate education improves preparedness for clinical practice	Rebecca Murphy Lonergan
P4-06-03: Barriers and Goals of Care Expressed by Patients Living with Advanced Breast Cancer during a Nurse Practitioner-Led Visit	Ginny Kirklin
P4-06-04: Exploring Unmet Dental Care Need and Delay Due to Cost between Breast Cancer Survivors and the General Population in the United States	Jincong Freeman
P4-06-05: Telehealth and cancer care delivery: Evaluating the impact of telehealth on patient access and treatment utilization at a comprehensive cancer center using real world data	Kelsey Natsuhara
P4-06-06: The Etiologic Causes of Diagnostic Delay in Locally Advanced Breast Cancer: A Multicentric Nationwide Trial	Guldeniz Karadeniz Cakmak
P4-06-07: The Impact of a Multidisciplinary Quality Assurance Conference on the Management of Inflammatory Breast Cancer	Huong (Carisa) Le- Petross
P4-06-08: Regional Disparities in Mammography Access in Brazil: The Impact on the Consolidation of Effective Breast Cancer Screening	DANIELLE MAIA
P4-06-09: Does Age Impact Patient Involvement in Treatment Decision Making: Results from the Canadian Breast Cancer Network (CBCN) Assessment Project	Cathy Ammendolea
P4-06-10: Impact of Online Education in Improving Clinicians' Knowledge of the Hot Topics in Breast Cancer Clinical Research	Zhizhi Fiske
P4-06-11: What do patients, doctors, and payers truly value? Developing a multi-criteria decision analytic tool that assesses the value of adjuvant hormonal plus CDK inhibitors in breast cancer	Omar Castillo- Fernandez
P4-06-12: Breast Cancer Hub (BCH) Case Study – Addressing Breast Cancer Challenges in Villages in India with Grassroots Sustainable Solution	Dr Lopamudra Das Roy
P4-06-13: Empowering the clinician and patient communities through the development of an accessible, online tool to support diagnosis of Inflammatory Breast Cancer (IBC)	Lindsey Anstine

P4-06-14: Closing gaps in the diagnosis and treatment journey by a collaborative process design in a social and non-profit association in Peru	MAURICIO LEON RIVERA
P4-06-15: Resource Utilization by Patients Living with Advanced Breast Cancer (ABC) Who Had a Nurse Practitioner-Led Visit	Ginny Kirklin
P4-06-24: The effects of two multimodal exercise programs (face-to-face vs online) on physical and functional outcomes in breast cancer survivors: A randomized control trial.	Monica Castellanos-Montealegre
P4-06-25: The impact of multimodal exercise program on physical and functional outcomes in breast cancer survivors: A randomized controlled trial.	Soraya Casla-Barrio
P4-06-26: Fertility Preservation in Young Women with Breast Cancer in Brazil: Patient Profiles and Challenges in a Real World Scenario	Caroline Avelar
P4-06-27: "The decrease in survival of breast cancer patients during the COVID-19 pandemic"	Arely Gonzalez
P4-06-28: Income and Geography: Key Drivers of Disparities in Breast Cancer Mortality	Emily McGovern
P4-06-29: The impact of cardiovascular disease on breast cancer stage at diagnosis	Kevin Nead
P4-06-30: Comprehensive Approach to Prevention: Cancer Risk Reduction and Education (CaRE) Program	Jessica Jones
P4-07-01: Comparative 10-Year Survival Analysis of Breast-Conserving Surgery Versus Mastectomy in Early-Stage Breast Cancer for Young Patients	Babette Salaets
P4-07-02: Concordance rate of 99mTc and ICG/near-infrared light detected sentinel-lymph nodes in primary breast cancer	Peter Kern
P4-07-03: LONG TERM PATIENT REPORTED OUTCOMES FOLLOWING THERAPEUTIC MAMMAPLASTY	Katherine Fairhurst
P4-07-04: Impact of Involved Margin Status and Radiotherapy on Local Recurrence and Regional Recurrence in Patients Who Underwent Nipple Sparing Mastectomy or Skin Sparing Mastectomy with Immediate Reconstruction	Hyoung Won Koh
P4-07-05: Breast Cancer and Local Therapy: Breast Conservation and Oncoplastic Surgery are Associated with Improved Quality of Life	Daniel Barbalho
P4-07-07: Comparative analysis of breast-conserving surgery using a 3D-printed breast surgical guide versus standard breast-conserving surgery in breast cancer patients treated with neoadjuvant chemotherapy	Ah Yoon Kim

P4-07-08: Targeted Axillary Dissection using magnetic seed placement in the axilla (mag-TAD) combined w/ dual tracer sentinel node procedure after neo-adjuvant systemic therapy (NST) in primary node pos breast cancer. Real-world evidence study in the UAE.	Ernest Luiten
P4-07-09: Does energy device improve operative procedure and postoperative management of total mastectomy with axillary lymph node dissection?	Toshiyuki Ishiba
P4-07-10: Ensuring the precise interpretation of intraoperative specimen 3D imaging is crucial in avoiding the need for additional surgery for patients.	Hannah Jeffery
P4-07-11: Intraoperative sentinel lymph node evaluation in patients with breast cancer undergoing surgery after neoadjuvant systemic therapy	Saskia Leonard
P4-07-12: Attitudes on mastectomy in sub-Saharan Africa; a systematic literature review exploring womanhood and femininity	Mikaela Belsky
P4-07-13: FACTORS ASSOCIATED WITH THE PRACTICE OF ONCOPLASTIC SURGERY AMONG BREAST SURGEONS IN BRAZIL: A NATIONAL SURVEY	Francisco Pimentel Cavalcante
P4-07-14: Male Breast Cancer: Real World Surgical Management	Rebekah Young
P4-07-15: Minimally Invasive Mastery: A Comparative Analysis of Endoscopic Mastectomy and Conventional Nipple-Sparing Mastectomy with Immediate Reconstruction in Patients with Early-Stage Breast Cancer - A Paradigm Shift in Breast Cancer Surgery	VORATAPE KIJTAVEE
P4-07-16: First line CDK4/6 inhibitors plus endocrine therapy versus chemotherapy for HR+/HER2- metastatic breast cancer patients in real world: a multicenter YOUNGBC-30 study.	Biyun Wang
P4-07-17: Clinical outcomes in the OPTIMA prelim (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) feasibility study.	Robert Stein
P4-07-19: Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial.	Joohyuk Sohn
P4-07-20: Is Distance to Treating Oncologist a Potential Prognostic Real-World-Factor for Patients with HR+/HER2- Advanced Breast Cancer? Results from the Non-Interventional Study PERFORM	Michael P Lux

P4-07-21: Prognostic analysis of operable HR-positive HER2-negative loco-regional recurrent breast cancer; A multi-institutional Retrospective Cohort Study	EMI TOKUDA
P4-07-22: Real world effectiveness of overall survival (OS) with palbociclib (PAL) plus (+) endocrine therapy (ET) in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) patients in Japan	Michiko Tsuneizumi
P4-07-23: Preliminary safety in the inavolisib + fulvestrant + ribociclib/abemaciclib arms of MORPHEUS-pan breast cancer: A Phase 1b/2 study of efficacy & safety of multiple treatment combinations in patients with metastatic/locally advanced breast cancer	Einav Nili Gal-Yam
P4-07-24: Prospective Cohort Study of Abemaciclib in Combination with Endocrine Therapy for Chemotherapy-Treated HR+/HER2- Metastatic Breast Cancer	Kazutaka Narui
P4-07-25: Verification of a Highly Sensitive, Circulating Cell-Free DNA and Exosomal RNA RT-qPCR Assay to Monitor ESR1 Mutations from a Liquid Biopsy	Kevin Kelnar
P4-07-26: CDK 4/6 inhibitor switching and associated dosing patterns in Swedish HR+/HER2- MBC patients	Daniel Nyqvist
P4-07-27: Real-world observational study of patients with endocrine-resistant, hormone receptor+, HER2- metastatic breast cancer in the first-line setting: Patient characteristics, PIK3CA mutation prevalence, treatments, and clinical outcomes	Preet Dhillon
P4-07-29: Analytical Validity of the Digistain Test in the Face of Variable Fixation Times: A Study from Charing Cross Hospital	Hemmel Amrania
P4-07-30: The prognostic and predictive value of Oncotype DX® in ER+/HER2-/pT2N0, cM0 Breast Cancer Patients	IOANNIS NATSIPOULOS
P4-08-01: pionERA Breast Cancer: Phase 3 study of first-line giredestrant vs fulvestrant, + a CDK4/6 inhibitor, in patients with estrogen receptor+, HER2- locally advanced/metastatic breast cancer with resistance to prior adjuvant endocrine therapy	Kevin Kalinsky
P4-08-02: Identifying unique transcriptomes associated with HER2+ breast cancer recurrence at the single-cell level.	Paola A. Marignani
P4-08-04: Selective activity of rogaratinib in PIK3CA- and ESR1-wild-type, FGFR1/2-amplified hormone receptor-positive breast cancer (HR+/HER2- BC): a co-clinical trial	Miguel Quintela-Fandino
P4-08-05: A Phase Ib/II trial of Lenvatinib plus Pembrolizumab plus Fulvestrant in ER+/HER2- Metastatic Breast Cancer (MBC)	Sherry Shen

P4-08-06: Onvansertib enhances the anti-tumor efficacy of trastuzumab deruxtecan in CDK4/6 inhibitor-resistant HR+/HER2-breast cancer patient-derived xenograft models	Sreeja Sreekumar
P4-08-07: Survival outcome in patients with metastatic breast cancer with low hormonal receptor expression	Ahrong Ham, Kyoung Eun Lee
P4-08-08: Real-world data on cyclin-dependent kinase 4/6 inhibitor switching in patients with first-line hormone receptor-positive, HER2-negative metastatic breast cancer	Lu Chen
P4-08-09: Phase 3, Randomized, Open-label TroFuse-010 Study of Sacituzumab Tirumotecan (sac-TMT) Alone & W/ Pembrolizumab vs. Treatment of Physician's Choice Chemotherapy in Patients With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer	Sara M. Tolaney
P4-08-10: Correlation between prior treatments on CDK4/6 Inhibitors Survival in Hormone receptor-positive metastatic breast cancer	ELINA RODRIGUEZ-MELENDZ
P4-08-11: Linc01588-V4 is UPR-downregulated lncRNA in a PERK-dependent manner and estrogen-responsive gene mediated cell proliferation and migration of ER+ breast cancer cells	Wen Liu
P4-08-12: Second-line, post-CDKi treatment of metastatic ER+ HER2-negative breast cancer (ER+mBC): The impact of a 25-minute CME video on treatment choices of community-based general medical oncologists (GMOs)	Neil Love
P4-08-13: Evaluating CYP3A4-Mediated Drug Interaction Risks for Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degradar, in Combination With Cyclin-Dependent Kinase (CDK)4/6 Inhibitors and Everolimus	Stefanie Drescher
P4-08-14: ALISertib in combination with endocrine therapy in patients with hormone receptor-positive, HER2-negative recurrent or metastatic breast CAncer: the phase 2 ALISCA-Breast1 study	Tufia C. Haddad
P4-08-15: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients with Metastatic Breast Cancer: A Phase 2 Randomized, Open-Label Study	Frances Valdes
P4-08-16: Modulating Gut Microbiota to enhance the efficacy of Immunotherapy in Triple Negative Breast Cancer (TNBC)	SAMARPAN MAJUMDER
P4-08-17: First-in-human Phase 1 study of BTX-9341, a first-in-class, CDK4/6 bifunctional degrader, as a monotherapy and in combination with fulvestrant in patients with advanced and/or metastatic HR+/HER2- breast cancer.	Amita Patnaik

P4-08-18: M6 metabolite enhances the efficacy of the Rac/Cdc42 inhibitor MBQ-167 in metastatic advanced breast cancer	Nilmary Grafals-Ruiz
P4-08-19: Phase I Safety and Efficacy Study of Autophagy Inhibition to Augment the Antiproliferative and Biological Effects of Low Dose Palbociclib plus Letrozole in Estrogen Receptor-Positive, HER2-negative Metastatic Breast Cancer (MBC)	Akshara Singareeka Raghavendra
P4-08-20: Trial in progress: A first-in-human phase 1a/b, dose-escalation/expansion study of BG-68501/ETX-197 (CDK2 inhibitor) as monotherapy or in combination with fulvestrant for patients with HR+/HER2- breast cancer and other advanced solid tumors	Alejandra Ragone
P4-08-21: Chlorogenic acid and cinnamaldehyde in combination demonstrate antimetastatic capabilities and induce apoptosis in MCF7 and MDA-MB-231 breast cancer cell lines via downregulation of the Akt pathway	Yusuff Olayiwola
P4-08-22: Overcoming Olaparib Resistance in BRCA-Mutated Triple-Negative Breast Cancer: Synergistic Potential of DNA Repair Pathway Inhibitors	Diana Hawkins-Westergard
P4-08-23: Preclinical characterization of DF1001, a first-in-class dual NK and T cell engager targeting HER2-high or HER2-low tumors	Laurens Lambert
P4-08-24: AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation (Trial in Progress)	Anthony Tolcher
P4-08-25: Overall survival in patients with HR+/HER2- advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy	Rachel Layman
P4-08-26: Trial in progress: First-in-human phase 1a/1b, dose-escalation/expansion study of BGB-43395 (CDK4 selective inhibitor) as monotherapy or combination therapy in Chinese patients with metastatic HR+/HER2- breast cancer & other advanced solid tumors	Jian Zhang
P4-08-27: PMD-026, a First-in-Class RSK Inhibitor, Overcomes Acquired Resistance to CDK4/6 Inhibitors or Aromatase Inhibitors in HR+/HER2- Breast Cancer Preclinical Models	Sandra Dunn
P4-08-28: Results of the Dose-Escalation Cohort of a Phase 1 Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and HR Low Positive Breast Cancer. DecipHER trial	Ricardo Costa

P4-08-29: Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer: an updated analysis	Cristiano Souza
P4-08-30: Preclinical Characterization and Safety of First-in-Class, brain penetrant ALC1 Inhibitor EIS-12656 in HRD cancers	Adrian Schomburg
P4-09-01: Contrast-enhanced ultrasound traced secondary sentinel lymph nodes in early-stage breast cancer to streamline sentinel lymph node biopsy----a preliminary study	Xiaoling Liu
P4-09-02: Multiparametric MRI and Transfer Learning for Predicting Positive Margins in Breast-Conserving Surgery: A Multi-Center Study	Xue Zhao
P4-09-03: Reoperation Rates Following Breast-Conserving Surgery in a Brazilian Cohort	Anne Dominique Nascimento Lima
P4-09-04: Vacuum-assisted biopsy (VAB) versus standard breast surgery among patients with pCR after neoadjuvant therapy.	Nikolay Amirov
P4-09-05: Trends in mastectomy for non-metastatic breast cancer patients in an institution with limited resources	Francisco Pimentel Cavalcante
P4-09-06: Oncologic Outcomes of Breast-Conserving Surgery versus Mastectomy after Neoadjuvant Chemotherapy: Results from a Contemporary Multicenter Cohort	Francisco Pimentel Cavalcante
P4-09-07:	Hui Dai
P4-09-08: Outcomes after Autologous Breast Reconstruction for Triple-Negative Breast Cancer among Black and White Patients	Mattia Mahmoud
P4-09-09: Prepectoral Implant-Based Breast Reconstruction: A New Standard of Care. Experience of a Chilean Breast Oncoplastic Surgery Group	Jaime Letzkus
P4-09-10: Evaluation of Axillary Treatment in Patients with Early Breast Cancer According to Study Z0011 in a Public Tertiary Hospital in the Federal District, Brazil	Thais Vivan
P4-09-11: The use of indocyanine green instead of blue dye for dual-tracer sentinel lymph node biopsy in breast cancer	Madison Kolbow
P4-09-12: Factors influencing axillary node clearance in early breast cancer care in the UK in 2023	Stuart A McIntosh
P4-09-13: Intraoperative assessment of margins in breast conserving therapy: Comparison of intraoperative specimen mammography and intraoperative pathologic evaluation	Susanne Briest
P4-09-14: Results of combined breast cancer treatment depending on various types of reconstruction after mastectomy and radiation therapy	Daria Ulrikh
P4-09-15: The Role of Axillary Reverse Mapping during Sentinel Lymph Node Biopsy in Breast Cancer Patients	Nikolay Amirov, Petr Krivorotko

P4-09-16: Progesterone Receptor Expression Significantly Correlates with Recurrence Score Regardless of Menopausal Status in HR+/HER2- BC Patients	Federica Martorana
P4-09-17: Oncotype DX® breast cancer assay in older patients: a real-life cohort	Clement Grosnon
P4-09-18: Adjuvant abemaciclib use and outcomes in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: a real-world analysis.	MONIQUE TAVARES
P4-09-19: Exploring cellular heterogeneity of localised breast cancers	Beata Kiedik
P4-09-20: Extended Endocrine Adjuvant therapy for Early HR+ Breast Cancer, Comparisons Between Molecular Expression Profiles	Lowell Hart
P4-09-21: Metastatic disease in patients with early breast cancer and a low Oncotype DX® Recurrence Score: A review of clinicopathological features	Javid Alibhai
P4-09-22: Distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2+ early breast cancer (EBC)	Sara Hurvitz
P4-09-23: Challenges and opportunities for CDK4/6i therapy in adjuvant early breast cancer	Richard Simcock
P4-09-24: Revealing the connection: Clinicopathological characteristics and Oncotype DX Scores in Invasive Lobular Breast Cancer	Iris Otoya, Zaida Morante
P4-09-25: Estrogen Receptor Expression and Clinical Outcomes in Breast Cancer: Insights from a Single-Center Study	Luisa Fernanda González-González
P4-09-26: Impact of NCCN/ASCO Guidelines and Epic Software Enhancement on Utilization of the Breast Cancer Index Test and its Role in the Quality of Cancer Care at Community Centers	Cindy Tran
P4-09-27: The clinical benefits of CDK 4/6 inhibitors and biomarker interactions on HR+/HER2- advanced breast cancer patients: an updated pairwise meta-analysis of randomized controlled trials and network meta-analysis	Sheng-Fan Wang
P4-09-28: Perioperative treatment regimens and efficacy outcome measures in early-stage HR+/HER2- breast cancer: A systematic literature review of randomized controlled trials	Peter Schmid
P4-09-29: PR status cannot predict Oncotype DX Recurrence Score®: a study in a Greek cohort of N0M0/ER+/PR-/HER2- breast cancer patients tested with Oncotype DX	VASILEIOS VENIZELOS

P4-09-30: The Impact Of Online Education On Clinician Knowledge, Competence, And Confidence In Understanding the Latest Clinical Trial Data for HR+/HER2- Early Breast Cancer With a High Risk of Recurrence	Urvi Patel
P4-10-01: Testosterone & Tamoxifen (T&T) trial: adding Testosterone to Tamoxifen in male breast cancer patients	Jasmine Moustaquim
P4-10-02: RYZ101 (225Ac-DOTATATE) ± pembrolizumab in estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced and unresectable or metastatic breast cancer progressing after prior therapy: the phase 1b/2 TRACY-1 study	Erica Mayer
P4-10-03: Potential risk factors for health-related quality of life (HRQoL) in palbociclib (PAL) plus endocrine therapy (ET) and ET alone patients with HR+/HER2- advanced breast cancer (ABC): exploratory analysis from 6-month longitudinal study (JBCRG-26)	Shigehira Saji
P4-10-04: Utility of genomic testing and targeted treatment for patients with hormone receptor-positive metastatic breast cancer	Himil Mahadevia
P4-10-05: LITESPARK-029: A Phase 2, Randomized, Open-label Study of Belzutifan Plus Fulvestrant in Patients W/ Estrogen Receptor Pos, HER2-Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous Endocrine Therapy	Bora Lim
P4-10-06: Preclinical characterization of BGB-43395, a potential best-in-class CDK4 selective inhibitor with potent pharmacodynamic and anti-tumor activity in HR+HER2- breast cancer models	Fernando Donate
P4-10-07: Evaluation of pharmacokinetics and safety of imlunestrant in participants with hepatic impairment	Xuejing Wang
P4-10-08: Impact of an Online Educational Activity on Oncologists' Knowledge and Confidence Regarding the Management of HR-Positive/HER2-Negative Metastatic Breast Cancer	Zhizhi Fiske
P4-10-09: Genomic Profiles of Early Progressors vs Exceptional Responders on CDK4/6i in ER+ HER2- Advanced Breast Cancer	Tim Kong
P4-10-10: Changing treatment paradigms and unmet needs in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC): Results from health records data	Alberto Montero

P4-10-11: The Impact of Live and Online Education on Clinical Knowledge, Competence, and Confidence in the Use of Novel Antibody–Drug Conjugate Therapy for HR-Positive Breast Cancer	Zhizhi Fiske
P4-10-12: Abemaciclib monotherapy after disease progression on prior CDK4/6 inhibitors in patients with metastatic hormone-receptor positive breast cancer	Sahar Shahamatdar
P4-10-14: Real-world palbociclib dose adjustment and outcomes in HR+/HER2- metastatic breast cancer: Flatiron database analysis	Rachel Layman
P4-10-15: Evaluating the APIS ESR1 Mutations Kit: Performance and LoD Testing in Varied Wildtype Backgrounds	Anna Gasior
P4-10-16: INX-315, an oral, potent and selective CDK2 inhibitor in patients with CDK4/6 inhibitor resistant ER+/HER2- breast cancer or CCNE1 amplified solid tumors: phase 1 monotherapy dose escalation	Antoinette Tan
P4-10-17: An Analysis of the Breast Cancer Vaccine Landscape	Michelle Tregear
P4-10-18: Potential predictive biomarkers for a fibroblast growth factor receptor (FGFR) inhibitor: Phase 1b trial of tasurgratinib (E7090) with endocrine therapies (ET) for ER+, HER2+ recurrent/metastatic breast cancer (BC) resistant to CDK4/6 inhibitors	Toshinari Yamashita
P4-10-20: First-in-human phase 1a, dose-escalation study of BGB-43395 (CDK4-selective inhibitor) as monotherapy and in combination with fulvestrant or letrozole in patients with metastatic HR+/HER2+ breast cancer and other advanced solid tumors	Timothy Yap
P4-10-21: Enhanced anti-tumor activity of zelenectide pevvedotin in triple negative breast cancer (TNBC) patients (pts) with NECTIN4 gene amplification (amp)	Niklas Klümper
P4-10-22: Eflapegrastim, a long-acting GCSF, administered the same day as chemotherapy in patients with early-stage breast cancer: Results from a multicenter, open-label, study	Lee Schwartzberg
P4-10-23: Preclinical anti-tumor activity of BB-1701, a HER2-targeting eribulin conjugated ADC, in HER2-low breast cancer PDx models.	Shogo Yamaguchi
P4-10-24: Extracellular matrix remodelling is a targetable feature of invasive lobular carcinoma (ILC)	Renee Flaherty
P4-10-25: Characterization and anti-tumor activity of BB-1701, a HER2-targeting eribulin-conjugated ADC, in preclinical models	Renee Jean-Toussaint

P4-10-26: PRISM high-throughput screening to elucidate how tumor microenvironments modulate drug responses of breast cancer cells	Blanche C. Ip
P4-10-27: Epigenetic Drug Profiling for Breast Cancer Therapy: A Focus on Receptor Modulation and Heterogeneity	Rahat Alam
P4-10-28: Efficacy, safety and biomarker results of AC699, a chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer	Erika Hamilton
P4-10-29: Repurposing hypertensive drugs for breast cancer therapies	Maninder Khosla
P4-10-30: Injectable novel hydrogel formulation for bacterial encapsulation	Arailym Myrzagaliyeva
P4-11-01: Retrospective analysis of outcomes of HR-positive/HER2-negative early-stage breast cancer patients from adjuvant GEICAM studies and El Álamo IV registry	Sonia Servitja
P4-11-02: Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer.	Hannah Majeski
P4-11-03: Predicting high risk hormone receptor (HR) positive Her-2 negative early breast cancer (BC) by artificial intelligence (AI) algorithms	Gul Basaran
P4-11-04: Correlative analysis of Breast Cancer Index with Body Mass Index for prediction of extended endocrine therapy benefit in the BCI Registry study	Natalia Siuliukina
P4-11-05: Aromatase inhibitors mediate specific gut-bug interactions to shift the microbiome and decrease inflammation during adjuvant treatment in breast cancer patients.	Katherine Cook
P4-11-06: Neoadjuvant anlotinib plus nab-paclitaxel based chemotherapy in patients with HER2-negative breast cancer: A prospective, single-arm, single-center, phase II clinical study	Huimin Meng, Ting Wang
P4-11-07: The Oncotype DX® test to guide adjuvant chemotherapy treatment decisions for early node-negative HR+/HER2- breast cancer patients in Japan: a cost-effectiveness analysis	Gebra Cuyún Carter
P4-11-08: Comparative analysis of clinician and AI decision making in HR+/HER2- early breast cancer.	Roberto Buonaiuto
P4-11-09: Epigenetic Alterations Affecting Cell Morphogenesis and Tumor Plasticity Pathways in Primary Tumors of Breast Cancer Patients with High Nodal Involvement	Sandra Iñiguez-Muñoz
P4-11-10: Long-term Outcome of Slowly Proliferating Luminal Type ILC versus IDC	Ji Won Yoo

P4-11-11: Real world data on breast cancer prognostication in India using CanAssist Breast- an indigenous test validated in global studies.	Somashekhar SP
P4-11-13: High Progesterone Receptor (PR/PGR) Expression Determined by APIS Breast Cancer Subtyping Kit Correlates with Oncotype Dx Recurrence Score	Anna Gasior
P4-11-14: Prescribing patterns and real-world clinical usage of adjuvant abemaciclib for early-stage, high-risk, hormone receptor positive breast cancer	Sneha Rajendran
P4-11-15: Variability in physician treatment decisions for HR+ / HER 2 negative Early Breast Cancer in young patients: a Latin-American survey	Dana Narvaez
P4-11-16: Improvement of Pathologic Complete Response Prediction with Plasma Cytokine Profiles in Hormone Receptor-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy	Francisco Ayala de la Peña
P4-11-17: Prognostic significance of complete cell cycle arrest compared to the CPS + EG scoring system in patients with HR+/HER2- breast cancer receiving neoadjuvant chemotherapy	Sohyun Moon
P4-11-18: Efficacy of anthracycline- and taxane-containing neoadjuvant chemotherapy for luminal HER2-negative BRCA-mutated breast cancer	Yaroslav Zhulikov
P4-11-19: An analysis of sexual dysfunction symptoms in hormone receptor positive breast cancer patients during adjuvant endocrine therapy in a single Brazilian center	Daniela Pereira
P4-11-20: Development of a method for detecting genetic mutations in early breast cancer using Plasma-Safe-SeqS technology and its clinical application.	Reika Yoshida
P4-11-21: The use of adjuvant Abemaciclib in HR+, HER2- early breast cancer: a multi-institutional UK experience.	Bahaaeldin Baraka
P4-11-22: Prognostic Value of high-risk Oncotype Recurrence Score (RS) and MammaPrint (MP) assay in Premenopausal African American (AA) Patients with Hormone-Positive (HR+), Node-Negative Breast Cancer (BC): A Study of the National Cancer Database (NCDB).	Devashish Desai
P4-11-23: Treatment Response to Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, HER2 Negative Early Breast Cancer Patients in Los Angeles County	Gene Yoshikawa

P4-11-24: Real-world data on high and intermediate-risk hormone receptor (HR)-positive HER2-negative early breast cancer patients prior to adjuvant CDK1/6i era	Winnie YEO
P4-11-25: Enhancing Care of HR+/HER2- Early Breast Cancer Patient At Risk of Recurrence Through an Expansive Curriculum	Urvi Patel
P4-11-26: Efficacy of neoadjuvant endocrine therapy versus chemotherapy in ER+ HER2-negative breast cancer: a single-center matched-cohort study. Preliminary results.	E.I. Kovalenko
P4-11-28: Breast Cancer Recurrence Risk Stratification with the 21-Gene Recurrence Score Assay - the Portuguese National Experience	Teresa Gantes Padrão
P4-11-29: Clinical Impact of 18F-fluoro-17b-fluoroestradiol (18F-FES) PET in Patients with Estrogen Receptor-Positive Breast Cancer	Samer Alkassis
P4-11-30: Assessing the APIS Breast Cancer Subtyping Kit for RNA-Based Risk Stratification in Older Patients: Swiss Cohort Findings	Anna Gasior
P4-12-01: Correlation between the Oncotype DX Recurrence Score® categories and progression-free survival of patients with primary metastatic estrogen-receptor positive and HER2-negative breast cancer	Marc Thill
P4-12-02: Patterns and predictors of disease progression and their impact on survival in patients receiving Cyclin D Kinase 4/6 inhibitors (CDK4/6i) for advanced Breast Cancer (aBC).	Sudhir Kumar
P4-12-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degradar, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Prelim Phase 1b Results	John Hilton
P4-12-04: Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2- MBC patients living in disadvantaged neighborhoods	Filipa Lynce
P4-12-05: Prescription patterns and preferences for CDK4/6 inhibitors among oncologists in Latin America	Andres Meraz-Brenez
P4-12-06: Real-world clinical practice PIK3CA mutation testing patterns in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2+) metastatic breast cancer (mBC)	Leah Park
P4-12-07: Cyclin-dependent kinase 4/6 inhibitors dose reduction in patients with endocrine resistant advanced breast cancer experiencing early disease progression	Marcin Kubeczko

P4-12-09: Cytotoxic treatment and survival after CDK4/6 inhibitors in patients with luminal metastatic breast cancer before the era of anti-body-drug-conjugates: Results from the Austrian AGMT_MBC-Registry	Gabriel Rinnerthaler
P4-12-10: UNIQUE MECHANISM OF ACTION OF ELACESTRANT SENSITIZES ESR1-MUTANT BREAST CANCER TO NOVEL THERAPEUTIC COMBINATIONS	Emily Zboril
P4-12-11: Large Oncosomes Loaded with circPEX13 Enhance Osteoclast Differentiation and Facilitate Breast Cancer Bone Metastasis	Jinpeng Luo
P4-12-12: Endocrine Therapy with or without Cyclin-dependent Kinase 4/6 Inhibitor for HR-Positive, HER-Negative, advanced breast cancer following progression on a prior CDK4/6 Inhibitor plus Endocrine Therapy: A Systematic Review and Meta-Analysis	Maria Agustina Callizo Bedoya
P4-12-13: CDK4/6 inhibitors (iCDK4/6) in breast cancer (BC): Is it possible to predict response?	Lucas Gouvêa
P4-12-14: Updated efficacy and safety of CDK4/6 inhibitors plus endocrine therapies in elderly HR+/HER2- metastatic or advanced breast cancer: patient-level network meta-analysis	Yun-Sheng Tai
P4-12-15: Key Factors Affecting Clinical Investigators Use of Oral SERDs in Current Management of ER-Positive, HER2-Negative, ESR1-Mutated (ER+/HER2-/ESR1+) Metastatic Breast Cancer That Has Relapsed After Treatment w/ a CDK4/6 Inhibitor/Endocrine Therapy	Neil Love
P4-12-16: Identification of CGT4255 an EGFR sparing, ErbB2 clinical development candidate with activity across activating mutations in systemic and CNS tumors	Mark J. Chicarelli
P4-12-17: Pre-clinical data and phase I design for PQ-203: a novel peptide-drug conjugate (PDC) targeting the SORT1 receptor in hormone receptor "Triple" Negative Breast Cancer (TNBC)	Andrew Zhai
P4-12-18: Discovery and characterization of ETX-636, a potential best-in-class, oral, small molecule, pan-mutant-selective PI3K α inhibitor	Robert Koncar
P4-12-19: Preclinical Characterization of a Novel PI3K α H1047R Mutant-Selective Inhibitor	Aaron C. Smith
P4-12-20: OKI-219 enhances activity of SOC therapies in double and triple combinations in pre-clinical PI3K α H1047R mutant breast cancer models	Molly Taylor

P4-12-21: Efficacy and Safety of MRG002 in Prior TKI-Treated HER2 Positive Breast Cancer Patients: A Single Arm, Open Label, Multicenter, Phase II Study	Qiang Liu
P4-12-22: Ergosterol Peroxide affects the VCP/ANKZF1 complex spatial relationship and interaction in IBC cells	Luz V. Arroyo-Cruz
P4-12-23: Z-Endoxifen-PROTAC, a novel drug for chemo-sensitive and-resistant Triple Negative Breast Cancer.	Swaathi Jayaraman
P4-12-24: Preclinical characterization of LY4045004, a next-generation, mutant-selective PI3K α inhibitor	Raymond Gilmour
P4-12-25: TARGETING BRCA-DEFICIENT CANCER CELLS WITH SMALL MOLECULE RAD52 INHIBITORS	Shiva Ostadrahimi
P4-12-26: Preclinical study of newly developed anti-breast cancer drug targeting sphingosine-1-phosphate utilizing a novel drug delivery system	Masayuki Nagahashi
P4-12-27: Exploring Stimulation Response of Cisplatin Prodrugs and Integrating Photothermal-Photoacoustic Dual-Modal Theranostics in Triple-Negative Breast Cancer through Ozone-mediated Photothermal Catalytic Nanosystem	Dan Zheng
P4-12-28: Discovery and Validation of Novel Small G Protein Inhibitor OSURALi for Targeting Triple Negative Breast Cancer	Dillon Richardson
P4-12-29: ETX-197/BG-68501, a potential best-in-class potent, selective, oral, small molecule CDK2 inhibitor, has anti-tumor activity in cancer models with Cyclin E amplification or deficiency in the Retinoblastoma 1 gene.	Daliya Banerjee
P4-12-30: The Impact of Beta Blocker Use on the Survival of Cancer Patients: A Systematic Review and Meta-Analysis	Katarzyna J. Jerzak